Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 172 of 172 entries
Sorted by: Best Match Show Resources per page
Development of Persistent Opioid Use After Cardiac Surgery.

JAMA cardiology

Brown CR, Chen Z, Khurshan F, Groeneveld PW, Desai ND.
PMID: 32584934
JAMA Cardiol. 2020 Aug 01;5(8):889-896. doi: 10.1001/jamacardio.2020.1445.

IMPORTANCE: The overuse of opioids for acute pain management has led to an epidemic of persistent opioid use.OBJECTIVE: To determine the proportion of opioid-naive patients who develop persistent opioid use after cardiac surgery and investigate the association between the...

Cite
Brown CR, Chen Z, Khurshan F, et al. Development of Persistent Opioid Use After Cardiac Surgery. JAMA Cardiol. 2020;5(8):889-896doi: 10.1001/jamacardio.2020.1445.
Brown, C. R., Chen, Z., Khurshan, F., Groeneveld, P. W., & Desai, N. D. (2020). Development of Persistent Opioid Use After Cardiac Surgery. JAMA cardiology, 5(8), 889-896. https://doi.org/10.1001/jamacardio.2020.1445
Brown, Chase R, et al. "Development of Persistent Opioid Use After Cardiac Surgery." JAMA cardiology vol. 5,8 (2020): 889-896. doi: https://doi.org/10.1001/jamacardio.2020.1445
Brown CR, Chen Z, Khurshan F, Groeneveld PW, Desai ND. Development of Persistent Opioid Use After Cardiac Surgery. JAMA Cardiol. 2020 Aug 01;5(8):889-896. doi: 10.1001/jamacardio.2020.1445. PMID: 32584934; PMCID: PMC7301303.
Copy Download .nbib Format: NLM
Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis.

Clinical and translational science

Kanhai KMS, Goulooze SC, van der Grond J, Harms AC, Hankemeier T, Verma A, Dent G, Chavez J, Meijering H, Groeneveld GJ.
PMID: 34799987
Clin Transl Sci. 2021 Nov 19; doi: 10.1111/cts.13181. Epub 2021 Nov 19.

The majority of disease modifying therapies for multiple sclerosis (MS) reduce inflammation, but do no't target remyelination. Development of remyelinating therapies will benefit from a method to quantify myelin kinetics in patients with MS. We labeled myelin in vivo...

Cite
Kanhai KMS, Goulooze SC, van der Grond J, et al. Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clin Transl Sci. 2021;doi: 10.1111/cts.13181.
Kanhai, K. M. S., Goulooze, S. C., van der Grond, J., Harms, A. C., Hankemeier, T., Verma, A., Dent, G., Chavez, J., Meijering, H., & Groeneveld, G. J. (2021). Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clinical and translational science, . https://doi.org/10.1111/cts.13181
Kanhai, Kawita M S, et al. "Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis." Clinical and translational science vol. (2021). doi: https://doi.org/10.1111/cts.13181
Kanhai KMS, Goulooze SC, van der Grond J, Harms AC, Hankemeier T, Verma A, Dent G, Chavez J, Meijering H, Groeneveld GJ. Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clin Transl Sci. 2021 Nov 19; doi: 10.1111/cts.13181. Epub 2021 Nov 19. PMID: 34799987.
Copy Download .nbib Format: NLM
Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance.

Journal of the American College of Cardiology

Nathan AS, Manandhar P, Wojdyla D, Nelson A, Fiorilli PN, Waldo S, Yeh RW, Rao SV, Fanaroff AC, Groeneveld PW, Wang TY, Giri J.
PMID: 34823664
J Am Coll Cardiol. 2021 Nov 30;78(22):2213-2217. doi: 10.1016/j.jacc.2021.09.862.

No abstract available.

Cite
Nathan AS, Manandhar P, Wojdyla D, et al. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. J Am Coll Cardiol. 2021;78(22):2213-2217doi: 10.1016/j.jacc.2021.09.862.
Nathan, A. S., Manandhar, P., Wojdyla, D., Nelson, A., Fiorilli, P. N., Waldo, S., Yeh, R. W., Rao, S. V., Fanaroff, A. C., Groeneveld, P. W., Wang, T. Y., & Giri, J. (2021). Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. Journal of the American College of Cardiology, 78(22), 2213-2217. https://doi.org/10.1016/j.jacc.2021.09.862
Nathan, Ashwin S, et al. "Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance." Journal of the American College of Cardiology vol. 78,22 (2021): 2213-2217. doi: https://doi.org/10.1016/j.jacc.2021.09.862
Nathan AS, Manandhar P, Wojdyla D, Nelson A, Fiorilli PN, Waldo S, Yeh RW, Rao SV, Fanaroff AC, Groeneveld PW, Wang TY, Giri J. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. J Am Coll Cardiol. 2021 Nov 30;78(22):2213-2217. doi: 10.1016/j.jacc.2021.09.862. PMID: 34823664.
Copy Download .nbib Format: NLM
Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury.

Blood

Poole LG, Kopec AK, Groeneveld DJ, Pant A, Baker KS, Cline-Fedewa HM, Flick MJ, Luyendyk JP.
PMID: 33569603
Blood. 2021 May 06;137(18):2520-2531. doi: 10.1182/blood.2020007415.

Intravascular fibrin clot formation follows a well-ordered series of reactions catalyzed by thrombin cleavage of fibrinogen leading to fibrin polymerization and cross-linking by factor XIIIa (FXIIIa). Extravascular fibrin(ogen) deposits are observed in injured tissues; however, the mechanisms regulating fibrin(ogen)...

Cite
Poole LG, Kopec AK, Groeneveld DJ, et al. Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury. Blood. 2021;137(18):2520-2531doi: 10.1182/blood.2020007415.
Poole, L. G., Kopec, A. K., Groeneveld, D. J., Pant, A., Baker, K. S., Cline-Fedewa, H. M., Flick, M. J., & Luyendyk, J. P. (2021). Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury. Blood, 137(18), 2520-2531. https://doi.org/10.1182/blood.2020007415
Poole, Lauren G, et al. "Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury." Blood vol. 137,18 (2021): 2520-2531. doi: https://doi.org/10.1182/blood.2020007415
Poole LG, Kopec AK, Groeneveld DJ, Pant A, Baker KS, Cline-Fedewa HM, Flick MJ, Luyendyk JP. Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury. Blood. 2021 May 06;137(18):2520-2531. doi: 10.1182/blood.2020007415. PMID: 33569603; PMCID: PMC8109015.
Copy Download .nbib Format: NLM
Showing 169 to 172 of 172 entries